The values of systemic inflammatory immune nutritional score in predicting the prognosis of immunotherapy for advanced gastric cancer
10.11904/j.issn.1002-3070.2025.01.006
- VernacularTitle:全身炎症免疫营养评分判断晚期胃癌免疫治疗预后的价值分析
- Author:
Ming MA
1
;
Wanying WANG
1
;
Yuli RUAN
1
;
Chao LIU
1
;
Yanqiao ZHANG
1
;
Zhigang MA
1
Author Information
1. 哈尔滨医科大学附属肿瘤医院消化内科二病房(哈尔滨 150081)
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
Immunotherapy;
Prognosis;
Systemic-inflammatory-immune-nutritional-score
- From:
Practical Oncology Journal
2025;39(1):39-48
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of this study was to explore the predictive value of the systemic inflammatory immune nutri-tion score(SIINS)for the prognosis of immunotherapy for advanced gastric cancer.Methods A retrospective analysis was conducted on the clinical data of 202 patients with advanced gastric cancer who received treatment with programmed death-1(PD-1)inhibitors at the Harbin Medical University Cancer Hospital from October 2018 to July 2022.The LASSO regression analysis was used to screen prognostic indicators,construct SIINS indicator,determine the optimal cutoff value for predicting prognosis using subject operating characteristic curves,and divide patients into the high SIINS and low SIINS groups.Independent prognostic factors for overall survival(OS)were determined using univariate and multivariate Cox regression analyses.Results Four indicators,including lymphocyte count,lactate dehydrogenase,and neutrophil lymphocytes,were selected to construct the SIINS index.The prognosis of patients in the high SIINS group was significantly lower than that in the low SIINS group(P<0.05).The results of the multifactorial Cox regression a-nalysis showed that the Eastern Cooperative Oncology Group(ECOG)score,Geriatric Nutritional Risk Index(GNRI),SIINS,treatment regimen,and number of treatment lines(P<0.05)could serve as the independent predictive prognosis of immunotherapy for advanced gastric cancer.Conclusion SIINS can predict the prognosis of patients with advanced gastric cancer treated with PD-1 inhibitors.
